On October 26, 2022 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, reported that it will be participating in the Bio-Europe conference being held virtually November 2 – 4, 2022 (Press release, Actinium Pharmaceuticals, OCT 26, 2022, View Source [SID1234622406]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Members of Actinium’s business development team will be participating in 1-on-1 meetings during the conference. Meetings with Actinium can be requested through the partneringONE system https://informaconnect.com/bioeurope/ or by contacting Andrew Olsen, Ph.D., Senior Associate, Scientific and Business Analysis at [email protected].

Bio-Europe is the largest European biopharma partnering meeting with over 4,000 attendees from 2,200 companies and over 27,000 1-on-1 meetings scheduled.